The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b
- 1 April 1999
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 52 (6) , 1277
- https://doi.org/10.1212/wnl.52.6.1277
Abstract
Article abstract The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon β-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.Keywords
This publication has 8 references indexed in Scilit:
- A Novel Sensitive and Selective Bioassay for Human Type I InterferonsJournal of Interferon & Cytokine Research, 1998
- Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosisNeurology, 1998
- To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions?Multiple Sclerosis Journal, 1997
- Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1bNeurology, 1996
- Guidelines for physicians with patients on IFN beta-1bNeurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995
- The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosisAnnals of Neurology, 1995